Odense, Denmark, September 10, 2018 / B3C newswire / -- RSP Systems A/S, the non-invasive diagnostics company, announces that it has completed second closing of its Series B round. This closing brings in an additional EUR 3,85 million making the round EUR 10,35 million in total. The proceeds will be used to fund clinical trials and to prepare for regulatory approval and market launch in Europe.
Existing, as well as new investors, have contributed to RSP Systems’ Series B round. Among these new investors is TRUMPF Venture, the corporate venture arm of the TRUMPF Group - the market and technology leader in machine tools and lasers.
RSP System’s CEO, Andreas Jenne, said, “We are grateful for the loyal support of existing shareholders and are excited to have attracted new and equally savvy shareholders in this second closing. The participation of TRUMPF Venture points to the fact that we are on track towards sourcing, production, and commercialization; the timing of this could not have been better.”
Dr. Dieter Kraft, managing director of TRUMPF Venture GmbH pointed out, "We are very happy to be part of the RSP support team. RSP Systems is expected to be the breakthrough innovator the medical industry has waited decades for. For TRUMPF the investment allows insights to new application areas of photonic systems where we can bring additional value based on our knowledge.”
About RSP Systems A/S
RSP Systems is a Danish MedTech company founded in 2006 as a spinout from the University of Southern Denmark, applying Raman spectroscopy for human diagnostics. The use of Raman spectroscopy in medical diagnostics has long eluded industry. RSP Systems has overcome the hurdles and offers the world’s first robust Raman spectrometry system for medical diagnostics. Over the past 6 years, the company has aimed for glucose monitoring and has now developed a prototype which shows target performance in clinical studies on diabetic patients at Odense University Hospital. The company uses this platform for its first non-invasive glucose monitor for diabetic patients.
The high-technology company TRUMPF offers production solutions in the machine tool and laser sectors. It is driving digital connectivity in the manufacturing industry through consulting, platform and software offers. TRUMPF is the world’s technological and market leader for industrial lasers and machine tools used in flexible sheet metal processing.
In 2017/18, the TRUMPF Group – which has about 13,500 employees – achieved sales of EUR 3.6 billion. With over 70 subsidiaries, it is represented in nearly all the countries of Europe, North and South America, and Asia. It has production facilities in Germany, France, Great Britain, Italy, Austria, Switzerland, Poland, the Czech Republic, the USA, Mexico, China, and Japan.
About TRUMPF Venture
TRUMPF Venture GmbH extends the company's comprehensive activities to promote innovation and to detect disruptive technologies at an early stage. It sees itself both as a venture capital investor and as a strategic partner for technology-oriented startups that will play a significant role in shaping the industry of the future.
With a current total volume of EUR 40 million, TRUMPF Venture GmbH invests in innovative start-ups with a focus on early stage financing. The requirements for consideration as a potential investment are strategic fit with TRUMPF, high innovation leverage in business model or technology, and risk adequate financial returns.
RSP Systems A/S
Head of Group Communications
+49 7156 303-31720